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1. Gemcitabine induced cell senescence but not apoptosis in human pancreatic cell lines 
which were resistance to gemcitabine. 
2. Gemcitabine induced cell senescence partly through gemcitabine induced ROS 
generation in human pancreatic cancer cell lines. 
3. Gemcitabine-induced senescence proceeded in vivo independently of CXCL8 
expression. 
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Patients with pancreatic ductal adenocarcinoma (PDAC) commonly require 
chemotherapy because they frequently develop metastatic disease or locally advanced 
tumors. Gemcitabine, an analogue of cytosine arabinoside, is commonly used for PDAC 
treatment. We observed that gemcitabine induced senescence phenotypes characterized 
by enhanced senescence-associated β-galactosidase (SA β-Gal) staining and increased 
expression of senescence-associated molecules in two human pancreatic cancer cell lines, 
Miapaca-2 and Panc-1, which exhibit resistance to gemcitabine but not L3.pl cells with a 
high sensitivity to gemcitabine. Gemcitabine-induced cell senescence can be inhibited by 
reactive oxygen species inhibitor, N-acetyl cysteine. Although gemcitabine also 
enhanced CXCL8 expression, anti-CXCL8 antibody failed to reduce 
gemcitabine-induced increases in SA β-Gal-positive cell numbers. These observations 
would indicate that cell senescence can proceed independently of CXCL8 expression, a 






Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor with in the exocrine 
compartment of pancreatic gland, and 5-year survival for all stages remains at less than 
5 % over the last few decades [1]. Even at the time of diagnosis, about 80% of patients 
are subjected to chemotherapy, due to metastatic disease or locally invasive tumors. 
Moreover, the rest of the patients are eligible for potentially curative resection but 
frequently develop local recurrence or distant metastasis after surgery and as a 
consequence, need adjuvant therapy consisting of chemotherapy and/or irradiation. 
Gemcitabine is an analogue of cytosine arabinoside (Ara-C) [2] and is used as a 
standard chemotherapeutic drug for PDAC treatment, alone or in combination with other 
chemotherapeutics[1, 3]. Like Ara-C, gemcitabine is a prodrug which requires cellular 
uptake and intracellular phosphorylation. It is transported across the cell membrane 
through multiple active nucleoside transporters located in the cell plasma membrane [4]. 
Inside the cell, gemcitabine is phosphorylated by deoxycytidine kinase to produce 
gemcitabine monophosphate (dFdCMP), which is further converted to active drug 
metabolites, gemcitabine diphosphate (dFdCDP) and gemcitabine triphophage (dFdCTP) 
[5]. dFdCTP directly inhibits DNA polymerase [6], cytidine triphosphate synthetase [7] 
and deoxycytidylate deaminase [8] , and is incorporated into DNA, thereby terminating 
chain elongation [9]. dFdCDP potently inhibits ribonucleotide reductase (RR), thereby 
decreasing deoxynucleotide pools necessary for DNA synthesis [10]， Despite its 
multiple intracellular targets, the resistance to gemcitabine often ensues [1] .  
 The term “cellular senescence” has been used to denote a stable and long-term loss 
of proliferative capacity, despite continued viability and metabolic activity [11]. 
Moreover, the overexpression of activated Ras proteins can induce a senescence-like 
phenotype, which is called oncogene-induced senescence (OIS) [12]. Cellular senescence 
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or OIS can induce the cells to undergo profound changes in their secretome, termed the 
senescence-associated secretion phenotype (SASP) [13, 14]. SASP is characterized by 
the overexpression of proinflammatory cytokines, interleukin (IL)-6 [15], and 
IL-8/CXCL8 [16]. OIS is presumed to serve as the first barrier of defense against cancer 
development [17], but can promote carcinogenesis by promoting inflammation arising 
from SASP [18,19]. 
 We previously observed that human pancreatic cancer cell lines exhibited enhanced 
CXCL8 expression, which is reminiscent of SASP, in the presence of gemcitabine [20]. 
Because Aird and colleagues revealed that oncogene-induced repression of RR resulted 
in a decrease in deoxyribonucleotide triphosphate levels and subsequently caused OIS 
[21], these observations prompted us to explore whether gemcitabine with a capacity to 
inhibit RR, can induce senescence-like phenotypes in human pancreatic cancer cells. 




Materials and Methods 
Cell lines and reagents 
   Miapaca-2 and Panc-1 cells were obtained from ATCC and were maintained in 
RPMI-1640 medium while L3.6pl cells were obtained from Dr. Isiah J. Fidler (MD 
Anderson Cancer Center, Houston, TX) and were maintained in minimum essential 
medium. Both media were supplemented with 10% fetal bovine serum.  
 
In vitro cell proliferation 
   Cell suspensions (2 × 103 cells /100 μl) were added to each well of 96-multi-well 
plates and incubated at 37oC for 24 hr. Then, gemcitabine was added to the indicated 
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concentrations and the cells were incubated for the indicated time intervals. The cell 
viability was determined by using the cell counting kit-8 (Dojindo Co. Ltd., Kumamoto, 
Japan). The ratios of cell numbers were determined by comparing the cell numbers at day 
0, and IC50 values for gemcitabine were calculated using logistic regression. 
 
Senescence-associated β-galactosidase (SA β-gal) staining 
   Human pancreatic cancer cell lines were seeded at a density of 5 x 104 cells/well in 
6-well plates. After gemcitabine treatment, the cells were fixed with 3% formaldehyde in 
PBS. In vivo experiment, frozen sections were cut at 5 μm and were fixed with 4% 
paraformaldehyde. Cells or frozen sections were stained overnight in X-gal staining 
solution consisting of 1 mg/ml X-gal, 40 mM citric acid/sodium phosphate buffer (pH 
6.0), 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM MgCl2 as previously described 
[22]. 
 
RNA isolation for RT-PCR 
   Total RNA was isolated and was reverse transcribed to cDNA as previously 
described [23]. Quantitative (q)RT-PCR was performed and mRNA amounts were 
normalized to the amounts of GAPDH as relative expression values as described 
previously [23]. The sequences of the used primers are listed in Table 1.  
 
Cell apoptosis analysis 
    After treatment with various concentrations of gemcitabine for 48 hr, the cells were 
harvested. Phosphatidylserine exposure level was determined by staining the cells with 
the human Annexin V-FITC Kit (Bender MedSystem, Vienna，Austria). At least 30,000 
stained cells were analyzed on a FACSCanto II system (BD Biosciences, San Jose, CA). 
 
Animal experiments 
    Miapaca-2 cells were suspended in HBSS at a concentration of 3.5 x 107 cells/ml 
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and 200 µl cell suspensions were injected subcutaneously into the back of BALB/c nu/nu 
mice (SLC, Shizuoka, Japan). When the tumor size reached 100 mm3, gemcitabine (30 
mg/kg body weight) was administered to tumor-bearing mice together with anti-human 
CXCL8 monoclonal antibody or control antibody (100 µg/body) according to the 
schedule illustrated in Figure 3B. At the indicated time points after the injection, tumors 
were removed for SA β-gal staining. All animal experiments were performed in 




    Data was analyzed statistically using methods indicated in each figure legend. p< 




The cell proliferation of different human pancreatic cancer cells after gemcitabine 
treatment. 
L3.6pl cells were highly sensitive to gemcitabine with IC50 of 0.002μM (Table 2). 
Consistent with the previous report [24], Miapaca-2 and Panc-1 cells were rather 
resistant to gemcitabine with IC50 of 0.7 and 5.5 μM, respectively (Table 2). Moreover, 
gemcitabine induced a marked apoptosis in L3.6pl cells as evidenced by enhanced 
annexin V staining, whereas only a marginal proportion of Miapaca-2 and Panc-1 cells 
became apoptotic upon exposure to gemcitabine (Figure 1). Thus, gemcitabine may 
inhibit cell proliferation by inducing apoptosis. 
 
Gemcitabine-induced cell senescence in gemcitabine-resistant pancreatic cancer 
cells. 
Given the potential of cell senescence to counteract irreversible cell death [25], we next 
examined the effects of gemcitabine on senescence. Gemcitabine efficiently induced 
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senescence in Miapaca-2 and Panc-1 cells in a dose-dependent manner (Figure 2A) but 
not in L3.6pl cells (data not shown), as evidenced by increased SA β-gal staining. 
Moreover, gemcitabine significantly increased the levels of senescence-associated 
molecules including P53, P21, P19, PML, and DCR2 in Miapaca-2 and Panc-1 cells, 
except P53 in Panc-1 cells (Figure 2B). Collectively, gemcitabine induced senescence 
but not apoptosis in Miapaca-2 and Panc-1 cells, the cell lines that are resistant to 
gemcitabine. 
 
Involvement of reactive oxygen species (ROS) in gemcitabine-induced cell 
senescence. 
We previously observed that gemcitabine induced ROS generation and that NAC with 
the capacity to scavenge ROS by interacting with OH· and H2O2 reduced 
gemcitabine-induced ROS generation [20]. Hence, we examined the effects of NAC on 
gemcitabine-induced senescence and observed that NAC decreased gemcitabine-induced 
increased SA β-gal-positive cell numbers (Figure 3A). Thus, gemcitabine induced 
cellular senescence partly via ROS generation. 
 
Gemcitabine-induced cell senescence in human pancreatic cancer in vivo. 
Gemcitabine treatment also increased SA β-gal-positive cell numbers when it was 
injected into a nude mouse bearing a tumor (Figure 3C). We previously observed that 
gemcitabine treatment enhanced intra-tumoral CXCL8 expression and that anti-CXCL8 
antibody administration reduced tumor formation when it was given with the 
combination of gemcitabine [20]. On the contrary, anti-CXCL8 antibody failed to reduce 




 Gemcitabine is widely used for the treatment of PDAC, but PDAC-derived cell lines 
exhibit a wide variation in responsiveness to gemcitabine. L3.6pl became mostly 
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apoptotic and extinguished in vitro in the presence of gemcitabine at doses lower than 
0.01 μM. On the contrary, Miapaca-2 and Panc-1 cells survived 1 µM but these cells 
exhibited senescence-associated phenotypes instead of undergoing apoptosis. Senescence 
generally contributes to the elimination of damaged cells by phagocytic cells, and to the 
subsequent promotion of tissue remodelling, similarly as apoptosis does [26]. Moreover, 
senescence can be induced in pre-cancerous or cancer cells under various conditions such 
as oncogene activation, chemotherapy, or radiotherapy, and can be a barrier against 
cancer progression, particularly in the case of OIS [11, 12]. Senescence is initially 
considered as an irreversible state of cellular arrest, similar to apoptosis which causes 
irreversible chromosomal DNA cleavage. However, the suppression of P53 in senescent 
cells can lead to rapid re-entry into cellular proliferation with loss of 
senescence-associated molecule expression [25]. Thus, chemotherapy-induced senescent 
cells may be in a reversible cellular arrest to escape cell death. This may account for 
gemcitabine-induced senescence in two pancreatic cancer cell lines, which are highly 
resistant to gemcitabine. 
    We previously unraveled the involvement of ROS generation in 
gemcitabine-induced CXCL8 expression [20]. Likewise, NAC, an inhibitor of ROS, 
significantly reduced gemcitabine-induced increases in SA-β-gal-positive cell numbers, 
suggesting that gemcitabine induced cell senescence partly through gemcitabine-induced 
ROS generation, as previously observed [27]. 
SASP, a typical feature of cell senescence, is characterized by enhanced expression 
of IL-6 and/or CXCL8 and its related chemokines in senescent cells [15, 16]. SASP is 
proposed to be able to promote and advance carcinogenesis [17, 18]. However, it still 
remains elusive on the roles of SASP in cell senescence. We previously observed that 
Miapaca-2 and Panc-1 cells did not express receptors for CXCL8, CXCR1 and CXCR2, 
but that anti-CXCL8 antibody reduced in vivo tumor formation with the combined 
administration of gemcitabine [20]. We explored the possibility of the paracrine effects 
of CXCL8 in gemcitabine-induced cell senescence, by administering anti-CXCL8 
antibody to tumor-bearing mice. However, the antibody failed to reduce 
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gemcitabine-induced increases in SA β-Gal-positive numbers. Thus, SASP may have few 
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Table 1. The list of the sequences of the primers used for qRT-PCR 
 





















Table 2. Effects of gemcitabine on the in vitro proliferation of human pancreatic cancer 
cell lines. IC50 values for gemcitabine were calculated using logistic regression. 
 













Legends to Figures 
Figure 1. Gemcitabine-induced apoptosis in gemcitabine-resistant pancreatic cancer 
cells. Cells were stained with the human Annexin V-FITC Kit. Representative results 
from 3 independent experiments in the upper panels. Mean and 1 SE were calculated for 
3 independent experiments, and are shown in the lower panels.  
 
Figure 2. A. Cells were incubated in the presence of the indicated concentrations of 
gemcitabine for the indicated time intervals. Cells were then subjected to SA β-gal 
staining to determine positive cell numbers. Mean and 1 SE were calculated for 3 
independent experiments and are shown in the lower panel. **, p<0.01, using one-way 
ANOVA followed by the Dunnett test, compared with untreated. B. Cells were then 
harvested and subjected to qRT-PCR to detect senescence-associated molecule mRNA. 
Mean and 1 SE were calculated for 3 independent experiments and are shown here. *, 
p<0.05; **, p<0.01 using Student’s t-test. 
 
Figure 3. Roles of ROS and CXCL8 in gemcitabine-induced cell senescence. A. The 
cells were subjected to SA β-Gal staining and the positive cell proportions were 
determined as described in Materials and Methods. Representative results from 3 
independent experiments are shown in the left panel. Mean and 1 SE were calculated for 
3 independent experiments and are shown here.*, p<0.05 using Student’s t-test. B. 
Schematic representation of the procedures of subcutaneous injection of Miapaca-2 cells. 
C. At 14 days after the initiation of gemcitabine treatment, tumors were removed and 
subjected to SA β-Gal staining. Positive cell proportions were determined, and mean and 
1 SE calculated for 3 independent experiments are shown here. ns., not significant. *, 
p<0.05 using one-way ANOVA followed by the Tukey-Kramer test. 



